You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
FDA正式紧急批准强生新冠疫苗使用 料月内供应逾2,000万剂
阿思达克 03-01 08:08
美国食品及药物管理局(FDA)已正式批准强生(Johnson & Johnson)(JNJ.US)新冠疫苗紧急在18岁或以上人士使用。当局指,强生的「一剂过」疫苗高度有效阻止严重新冠,包括新冠变种。署理总监Janet Woodcock表示,批准该款疫苗将扩大疫苗供应,亦为对付新冠的最佳医学方案。

根据临床测试,强生疫苗在美国、南非及巴西的有效率分别为85.9%、81.7%及87.6%。在3.93万名志愿测试者中,避免严重新冠的有效率为85.4%,但若计及温和徵状的预防有效率仅为66.1%。疫苗在不同种族及年龄的有效率差别不明显。

《路透》报道指,强生新冠疫苗经已开始出货,美国政府将於明日(2日)起开始分发。公司预计3月底交付逾2,000万剂,今年上半年交付1亿剂。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account